Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i. - Trial NCT06393348
Access comprehensive clinical trial information for NCT06393348 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shandong Suncadia Medicine Co., Ltd.
Timeline & Enrollment
Phase 2
Jun 01, 2024
Nov 01, 2025
Primary Outcome
Change in HbA1c from baseline at Week 16
Summary
2 weeks screening period, 3 weeks run-in period, 16 weeks double-blind treatment period, to
 evaluate the Safety and Efficacy of HRS-7535 in Subjects with Type 2 Diabetes who have
 Inadequate Glycemic Control on Metformin and SGLT2i.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06393348
Non-Device Trial